TP53 and leiomyosarcoma: TP53 mutation was significantly more frequent in leiomyosarcoma (16/45, 36%), and other sarcomas (13/34, 38%) rather than in liposarcoma (5/38, 13%), and synovial sarcoma (1/17, 6%) (p = 0.009).